WEB On July 20 2023 Idorsia sold its operating businesses in the Asia Pacific ex-China region to Sosei. WEB Allschwil Switzerland October 24 2023 IDIA today announced its financial results. IDIA today announced its financial results for the first half of 2023. WEB On July 21 2023 Idorsia announced that it has launched a cost reduction initiative with the target to reduce cash-burn at. WEB Allschwil Switzerland September 6 2023 IDIA today announced that it has entered. IDIA today announced its financial results for the first half of 2023. WEB Idorsia announces financial results for the first quarter 2023 QUVIVIQ now the leading branded. IDIA today announced its financial results for the first quarter of 2023..
WEB On July 20 2023 Idorsia sold its operating businesses in the Asia Pacific ex-China region to Sosei. WEB Allschwil Switzerland October 24 2023 IDIA today announced its financial results. IDIA today announced its financial results for the first half of 2023. WEB On July 21 2023 Idorsia announced that it has launched a cost reduction initiative with the target to reduce cash-burn at. WEB Allschwil Switzerland September 6 2023 IDIA today announced that it has entered. IDIA today announced its financial results for the first half of 2023. WEB Idorsia announces financial results for the first quarter 2023 QUVIVIQ now the leading branded. IDIA today announced its financial results for the first quarter of 2023..
Globenewswire
Morgan Healthcare Conference Adapting Idorsia for sustainable value creation. WEB Allschwil Switzerland November 3 2023 IDIA announced today that further data for aprocitentan Idorsias investigational. WEB Get all the latest information about our stock and see what the covering analysts think about the companys future performance. WEB Allschwil Switzerland October 24 2023 IDIA today announced its financial results for the first nine months of 2023. Net revenue HY 2023 at CHF 51 million US GAAP operating expenses HY 2023 at CHF 426 million and non-GAAP operating..
IDIA today announced that it has entered into agreements for a significant global research and development collaboration with Viatris Inc. . IDIA today announced that the US Food and Drug Administration FDA has approved QUVIVIQ daridorexant 25 mg and 50 mg for the treatment of adult patients. Aprocitentan Approval Is A Vital News 22 2024 1149 AM ET Idorsia Ltd IDRSF Stock 1 Comment. IDIA today announced its financial results for the first nine months of 2023 Transaction with Sosei Heptares hereafter referred as the..
Delco Today
IDIA today announced that it has entered into agreements for a significant global research and development collaboration with Viatris Inc. IDIA today announced its financial results for the first nine months of 2023 Transaction with Sosei Heptares hereafter referred as the. Aprocitentan Approval Is A Vital News 22 2024 1149 AM ET Idorsia Ltd IDRSF Stock 1 Comment. WEB Idorsia Media release US FDA approves Idorsias once-daily TRYVIO aprocitentan the first and only endothelin receptor antagonist for the treatment of high blood pressure not. IDIA today announced positive top-line results of PRECISION the Phase 3 study investigating aprocitentan Idorsias dual endothelin receptor antagonist for the treatment..
Comments